Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan.

ABSTRACT:

Background

Real-world clinical data on psoriasis patients receiving different biological agents is needed, especially in Asian populations.

Objectives

Our aim is to compare and analyze the efficacy and safety profile of four biological agents (etanercept, adalimumab, ustekinumab and secukinumab) in a real-world setting in Taiwan.

Methods

We retrospectively analyzed the clinical data of all patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 10) who received etanercept, adalimumab, ustekinumab or secukinumab between January 2011 and December 2018 in a tertiary hospital in Taiwan.

Results

A total of 119 treatment episodes in 75 patients were included in this study. Ustekinumab was used in 49 treatment episodes, followed b

SUBMITTER: Chen YC 

PROVIDER: S-EPMC7771674 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature